Vitro Announces Co-Sponsoring of Keystone Symposium on Stem Cells
Vitro Diagnostics, Inc. (dba Vitro Biopharma) announced co-sponsoring of the Keystone Symposium on cell stems that is going to be held at the Keystone Resort Conference Center from February 15- February 20, 2010. The company is best known for adult stem cell applications, US patents for adult stem cells production and pending US patents for iPS cell generation. At the meeting, Vitro Biopharma will present more information about the research concerning its pending patent for alternative technology for iPS cell generation.
The iPS cells are believed to have the same abilities as human embryonic stem cells including development into any type of cells in the body. Scientists all over the world intensively work on the technology for iPS cell generation with aim to develop an effective generation of stem cells without the use of controversial human embryonic stem cells.
The first technology for production of iPS cells was reported to be developed in 2007 and involved genetic engineering of fibroblast cells and increased expression of four genes. Vitro’s patent pending technology is notable for increased expression of one gene (POU5-F1) only which is believed to be the main regulator of pluripotency. Thus iPS cell generation would not require genetic engineering which is the main obstacle for the use of iPS cells for commercial and therapeutic purposes.
Vitro’s chief executive officer Dr. Jim Musick has stated that his company is proud to be the co-sponsor of the symposium on stem cells where scientists from all over the world will present the progress that was made in the research of iPS cells. He also said that Vitro has completed its first studies concerning the technology for generation of iPS cells involving expression of the gene known as POU5-F1 and that the results will be presented at the Keystone Symposium.
Subscribe to the comments for this post